C-suite
Since his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and Cassava, the FTC alleges.
The first-time CEO says her own sponsors took chances on her—and that industry leaders need to do the same to rebuild momentum for gender equity.
The person you expect to address the company’s problems should know the challenges your business faces. Not having that context will limit what they can accomplish.
CEO Matt Gline is juggling Roivant Sciences’ first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.
Last year, 11 major M&A deals were signed with women-led biotechs. The industry is nowhere near on track to meet that bar for 2026.
Strange and bittersweet. That’s how Claire Mazumdar describes her plan to step down from the top spot at Bicara, a biotech she helped form, and head out on parental leave before transitioning into a new role.
After achieving clinical validation earlier this year, ReCode Therapeutics has called up a new CEO to take on the mission of advancing programs for cystic fibrosis and primary ciliary dyskinesia through the clinic.
Novo has “gone shopping” to fill pipeline gaps, with a focus on obesity and diabetes, plus an expansion in blood and endocrine disorders, liver diseases and cardiovascular conditions.
Analysts tentatively welcomed Novo’s new corporate rebrand—so long as it comes with a larger change to the company’s overall business strategy.
Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
PRESS RELEASES